Endogenous bystander killing mechanisms enhance the activity of novel FAP‐specific CAR‐T cells against glioblastoma
Clinical & Translational Immunology · 2024-01 · 13 (7)
DOI: 10.1002/cti2.1519 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical & Translational Immunology, online erschienen am 05.07.2024. Verfasst von Wenbo Yu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Cancer Biology SA Pathology and University of South Australia Adelaide SA Australia. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council, Tour de Cure, Cancer Council South Australia.
Abstract (Originalsprache)
Objectives
CAR‐T cells are being investigated as a novel immunotherapy for glioblastoma, but clinical success has been limited. We recently described fibroblast activation protein (FAP) as an ideal target antigen for glioblastoma immunotherapy, with expression on both tumor cells and tumor blood vessels. However, CAR‐T cells targeting FAP have never been investigated as a therapy for glioblastoma.
Methods
We generated a novel FAP targeting CAR with CD3ζ and CD28 signalling domains and tested the resulting CAR‐T cells for their lytic activity and cytokine secretion function in vitro (using real‐time impedance, flow cytometry, imaging and bead‐based cytokine assays), and in vivo (using a xenograft mimicking the natural heterogeneity of human glioblastoma).
Results
FAP‐CAR‐T cells exhibited target specificity against model cell lines and potent cytotoxicity against patient‐derived glioma neural stem cells, even when only a subpopulation expressed FAP, indicating a bystander killing mechanism. Using co‐culture assays, we confirmed FAP‐CAR‐T cells mediate bystander killing of antigen‐negative tumor cells, but only after activation by FAP‐positive target cells. This bystander killing was at least partially mediated by soluble factors and amplified by IL‐2 which activated the non‐transduced fraction of the CAR‐T product. Finally, a low dose of intravenously administered FAP‐CAR‐T cells controlled, without overt toxicity, the growth of subcutaneous tumors created using a mixture of antigen‐negative and antigen‐positive glioblastoma cells.
Conclusions
Our findings advance FAP as a leading candidate for clinical CAR‐T therapy of glioblastoma and highlight under‐recognised antigen nonspecific mechanisms that may contribute meaningfully to the antitumor activity of CAR‐T cells.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Centre for Cancer Biology SA Pathology and University of South Australia Adelaide SA Australia.
- Cancer Clinical Trials Unit Royal Adelaide Hospital Adelaide SA Australia.
- Adelaide Medical School The University of Adelaide Adelaide SA Australia.
ORCID-Profile: Lisa M Ebert
Förderung
- National Health and Medical Research Council
- Tour de Cure
- Cancer Council South Australia
- Mark Hughes Foundation
- Neurosurgical Research Foundation
Zitieren
APA
Yu, W., Truong, N. T., Polara, R., Gargett, T., Tea, M. N., Pitson, S. M., Cockshell, M. P., Bonder, C. S., Ebert, L. M., & Brown, M. P. (2024). Endogenous bystander killing mechanisms enhance the activity of novel FAP‐specific CAR‐T cells against glioblastoma. Clinical & Translational Immunology, 13(7). https://doi.org/10.1002/cti2.1519
Vancouver
Yu W, Truong NT, Polara R, Gargett T, Tea MN, Pitson SM, et al. Endogenous bystander killing mechanisms enhance the activity of novel FAP‐specific CAR‐T cells against glioblastoma. Clinical & Translational Immunology. 2024;13(7). doi:10.1002/cti2.1519
BibTeX
@article{Yu2024,
author = {Yu, Wenbo and Truong, Nga Th and Polara, Ruhi and Gargett, Tessa and Tea, Melinda N and Pitson, Stuart M and Cockshell, Michaelia P and Bonder, Claudine S and Ebert, Lisa M and Brown, Michael P},
title = {Endogenous bystander killing mechanisms enhance the activity of novel FAP‐specific CAR‐T cells against glioblastoma},
journal = {Clinical & Translational Immunology},
year = {2024},
volume = {13},
number = {7},
doi = {10.1002/cti2.1519}
}
EUVIMED